Extended-release quetiapine fumarate ( DrugBank: Quetiapine )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 13 | Multiple sclerosis/Neuromyelitis optica | 1 |
13. Multiple sclerosis/Neuromyelitis optica
Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02087631 (ClinicalTrials.gov) | December 2014 | 12/3/2014 | Safety and Tolerability of Quetiapine in Multiple Sclerosis | A Dose-finding, Safety and Tolerability Trial of Extended-release Quetiapine in Relapsing-remitting and Progressive Multiple Sclerosis | Multiple Sclerosis | Drug: Extended-release quetiapine fumarate | University of Calgary | Multiple Sclerosis Society of Canada | Completed | 18 Years | 65 Years | All | 14 | Phase 1/Phase 2 | Canada |